A tumor and immune related miRNA signature predicts progression-free survival of melanoma patients treated with ipilimumab
Ahmad Tarhini, Priyanka Vallabhaneni, Theofanis Floros, William A. LaFramboise, Panayiotis V. Benos and Lucas Santana dos Santos. DOI: 10.1158/1538-7445.AM2016-473 Published July 2016 Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA Abstract Background Patients with regionally advanced melanoma were treated with neoadjuvant ipilimumab in a previously reported study (Tarhini et al, PLOS One 2014). MicroRNA (miRNA) expression profiles of tumors of treated patients were investigated for
Read more